Dr Mara Zeissig

Group Head, T Cell Immunotherapy Laboratory

South Australian Immunogenomics Cancer Institute

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Group Head, T cell Immunotherapy Lab, Tumour Inflammation and Immunotherapy Program, SAiGENCI

My Research
Career
Publications
Grants and Funding
Contact

Mara Zeissig's research lab is focused on improving response to T-cell based immunotherapies in solid cancers, with a focus on lung and pancreatic cancers. We use a range of approaches, including genetically engineered mouse models and sophisticated CRISPR-Cas9 genetic screening techniques to understand how tumours evade the immune system and identify immune modulators to increase the efficacy of immunotherapy in solid tumours.

Appointments

Date	Position	Institution name
2024 - ongoing	Group Head	University of Adelaide
2022 - ongoing	Senior Research Officer	Walter and Eliza Hall Institute of Medical Research
2020 - 2022	Research Officer	Monash University

Language Competencies

Language Competency

German Can read, speak and understand spoken

Spanish - Latin American Can read, write, speak and understand spoken
Education

Date Institution name Country Title

2013 - 2015 University of Adelaide Australia Bachelor of Science (Advanced)

University of Adelaide Australia PhD (Medicine)
Research Interests

Cancer Cell Biology Cancer Therapy Tumour Immunology Solid Tumours

Language	Competency
German	Can read, speak and understand spoken
Spanish - Latin American	Can read, write, speak and understand spoken

Date	Institution name	Country	Title
2013 - 2015	University of Adelaide	Australia	Bachelor of Science (Advanced)
	University of Adelaide	Australia	PhD (Medicine)

Journals

Year	Citation
2024	Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Wallington-Gates, C. T., Spencer, A., . . . Zannettino, A. C. W. (2024). Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines. Leukemia Research, 139, 107469-1-107469-8. DOI Scopus1 Europe PMC1
2023	Zeissig, M. N., Ashwood, L. M., Kondrashova, O., & Sutherland, K. D. (2023). Next batter up! Targeting cancers with KRAS-G12D mutations. Trends in Cancer, 9(11), 955-967. DOI Scopus30 Europe PMC17
2022	Goh, P. K., Wiede, F., Zeissig, M. N., Britt, K. L., Liang, S., Molloy, T., . . . Tiganis, T. (2022). PTPN2 elicits cell autonomous and non–cell autonomous effects on antitumor immunity in triple-negative breast cancer. Science Advances, 8(8), 22 pages. DOI Scopus23 Europe PMC15
2022	Wiede, F., Lu, K. H., Du, X., Zeissig, M. N., Xu, R., Goh, P. K., . . . Tiganis, T. (2022). PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer Discovery, 12(3), 752-773. DOI Scopus73 Europe PMC59
2020	Graziani, G., Herget, G. W., Ihorst, G., Zeissig, M., Chaidos, A., Auner, H. W., . . . Engelhardt, M. (2020). Time from first symptom onset to the final diagnosis of multiple myeloma (MM)–possible risks and future solutions: retrospective and prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network’ (EMN) analysis. Leukemia and Lymphoma*, 61(4), 875-886. DOI Scopus16 Europe PMC12
2020	Zeissig, M. N., Hewett, D. R., Panagopoulos, V., Mrozik, K. M., To, L. B., Croucher, P. I., . . . Vandyke, K. (2020). Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica, 106(12), 3176-3187. DOI Scopus16 WoS8 Europe PMC10
2020	Zeissig, M. N., Zannettino, A. C. W., & Vandyke, K. (2020). Tumour dissemination in multiple myeloma disease progression and relapse: A potential therapeutic target in high-risk myeloma. Cancers, 12(12), 3643-1-3643-20. DOI Scopus7 WoS6 Europe PMC6
2017	Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463. DOI Scopus44 WoS37 Europe PMC32

Conference Papers

Year	Citation
2017	Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2α Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.

Conference Items

Year	Citation
2019	Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Engelhardt, M., To, L. B., . . . Vandyke, K. (2019). Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI

2023 - 2024 Cure Cancer Australia Foundation Early Career Researcher Grant

2023 - 2026 Victorian Cancer Agency Early Career Fellowship

Position: Group Head, T Cell Immunotherapy Laboratory
Phone: 83134474
Email: mara.zeissig@adelaide.edu.au
Campus: West End Health Precinct
Building: AHMS - Adelaide Health and Medical Sciences, floor Ninth Floor
Room: 9070
Org Unit: South Australian Immunogenomics Cancer Institute

Dr Mara Zeissig

Appointments

Language Competencies

Education

Research Interests

Journals

Conference Papers

Conference Items

Connect With Me

External Profiles

Other Links